The Tumor Microenvironment (Record no. 110669)

000 -LEADER
fixed length control field 05795nam a22004575i 4500
001 - CONTROL NUMBER
control field 978-1-4419-6615-5
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20140220084510.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 100907s2010 xxu| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781441966155
-- 978-1-4419-6615-5
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-1-4419-6615-5
Source of number or code doi
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC261-271
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED062000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 614.5999
Edition number 23
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Bagley, Rebecca G.
Relator term editor.
245 14 - TITLE STATEMENT
Title The Tumor Microenvironment
Medium [electronic resource] /
Statement of responsibility, etc edited by Rebecca G. Bagley.
264 #1 -
-- New York, NY :
-- Springer New York :
-- Imprint: Springer,
-- 2010.
300 ## - PHYSICAL DESCRIPTION
Extent XVIII, 770 p.
Other physical details online resource.
336 ## -
-- text
-- txt
-- rdacontent
337 ## -
-- computer
-- c
-- rdamedia
338 ## -
-- online resource
-- cr
-- rdacarrier
347 ## -
-- text file
-- PDF
-- rda
490 1# - SERIES STATEMENT
Series statement Cancer Drug Discovery and Development
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Physiological Parameters -- Combination Strategies Targeting Hypoxia Inducible Factor 1 (HIF-1) for Cancer Therapy -- The Tumor Microenvironment: New Insights into Regulation of Tumor pH by Carbonic Anhydrases -- Hypoxia, Gene Expression, and Metastasis -- Molecular Mechanisms Regulating Expression and Function of Cancer-Associated Carbonic Anhydrase IX -- Glycolytic Pathway as a Target for Tumor Inhibition -- Malignant Cells -- Aberrant DNA Methylation in Cancer Cells -- DNA Repair and Redox Signaling -- Cancer Stem Cells and Microenvironment -- Epithelial–Mesenchymal Transition in Development and Diseases -- Invasion and Metastasis -- Dormancy of Disseminated Tumor Cells: Reciprocal Crosstalk with the Microenvironment -- Vasculature And Stroma -- Impact of Endothelial Progenitor Cells on Tumor Angiogenesis and Outcome of Antiangiogenic Therapy: New Perspectives on an Ongoing Controversy -- Bone Marrow Derived Mesenchymal Stem/Stromal Cells and Tumor Growth -- Integrin Signaling in Lymphangiogenesis -- Role of Pericytes in Resistance to Antiangiogenic Therapy -- Tumour-Promoting Stromal Myofibroblasts in Human Carcinomas -- Immune-Mediated Cells -- Mast Cells and Tumor Microenvironment -- Macrophages in the Tumor Microenvironment -- The Prognostic Significance of Tumor-Infiltrating Lymphocytes -- The Pro-inflammatory Milieu and Its Role in Malignant Epithelial Initiation -- Natural Killer Cells for Adoptive Immunotherapy -- Extracellular Matrix -- Fibronectin -- Collagen in Cancer -- Integrins and Cancer -- Matrix Metalloproteinases and Cancer Cell Invasion/Metastasis -- Tetraspanins and Cancer Metastasis -- Secreted Proteins -- Chemokines and Metastasis -- Transforming Growth Factor-? in Lung Cancer, Carcinogenesis, and Metastasis -- Cooperative Interactions Between Integrins and Growth Factor Signaling in Pathological Angiogenesis -- The Extracellular Matrix and the Growth and Survival of Tumors -- Secreted Growth Factors as Therapeutic Targets -- Adrenomedullin.
520 ## - SUMMARY, ETC.
Summary, etc The field of cancer biology and developmental therapeutics is continually evolving as new methodologies are developed and new targets are discovered. Although multiple therapeutics directly target the malignant cells these drugs rarely prevent recurrence of disease or the progression of metastasis. The complex biology of tumors presents challenges in designing treatments that will eliminate the malignant cells as well as the supporting network of vasculature and stroma that allows for the comparison of tumors to developing organs in embryos. In addition to blood vessels and malignant cells, tumors consist of fibroblasts, immune and inflammatory cells, and a myriad of proteins that comprise the extracellular matrix. Effective eradication of malignant disease requires therapeutic strategies that factor in targeting the tumor microenvironment. In the past decade, a new class of anticancer drugs has emerged that interferes with tumor angiogenesis; however the clinical benefit from treatment with the first generation antiangiogenic agents added to the standard of care is often modest. Thus, there remains a critical need to understand the tumor microenvironment and to develop anti-cancer therapies that address this aspect of malignant disease. The first edition of The Tumor Microenvironment is intended to give a current perspective on the role of the tumor microenvironment in malignant progression and detail strategies for novel therapies directed towards the cellular matrix. This book explores the many biological and physiological aspects of the tumor as a tissue and includes chapters on the variety of cells that influence tumor growth and spread as well as the cell-associated and soluble proteins that can promote invasion and metastasis. Several chapters describe endothelial cells and pericytes that form tumor vasculature. Insights into the role of progenitor and stem cells are included. The contribution of the supporting stroma is addressed in addition to cell-cell signaling and cell-matrix interactions. Additional chapters describe the influence of infiltrating cells of the immune system on tumor growth. The Tumor Microenvironment is the definitive text detailing cutting edge research by experts in the field and will be a valued resource in the study of this important area of cancer biology for many years to come.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Oncology.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Toxicology.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Biomedicine.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cancer Research.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Pharmacology/Toxicology.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9781441966148
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title Cancer Drug Discovery and Development
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://dx.doi.org/10.1007/978-1-4419-6615-5
912 ## -
-- ZDB-2-SME

No items available.

2017 | The Technical University of Kenya Library | +254(020) 2219929, 3341639, 3343672 | library@tukenya.ac.ke | Haile Selassie Avenue